NEW YORK, Oct. 9, 2013 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Ariad Pharmaceuticals, Inc. ("Ariad" or the "Company") (NasdaqGS: ARIA). Such investors are advised to contact Peretz Bronstein or his investor Relations coordinator Eitan Kimelman at firstname.lastname@example.org or 212-697-6484.
The investigation concerns whether Ariad and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On October 9, 2013, shares of Ariad fell $11.58 or 67.56% during intraday trading to trade at $5.56 after the company announced that it was putting a hold on new patient enrollment for tests on its leukemia drug Iclusig and that the drug causes more side effects than earlier communicated. Simultaneously, the FDA placed a partial clinical hold on all new patient enrollment in clinical trials of Iclusig.
If you are aware of any facts relating to this investigation, or purchased shares of Ariad, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC